Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue: +16.7%
EPS: +747.6%
Free cash flow: −4.76%
Total debt: −2.66%

Quarter to September 2026, against a year earlier

156.00 0.66 −0.42%

Follow ALNY

Alert me

Market cap: $21.0B
P/E: 7.9×
Fwd P/E: 13.5×
Dividend yield: —
F-score: 6/9
Altman Z: 7.30
Beneish M: −1.95
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. 10-Q filed Jul 30, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Jul 30, 2026 · accepted 8:11 AM ET · Document on sec.gov · Filing index

Red flags

Covenant breach Jul 30, 2026
Alnylam Pharmaceuticals, Inc.’s 10-Q reports a breach of a debt covenant, or a waiver to avoid one

The Revolving Credit Agreement contains customary affirmative and negative covenants and conditions to borrowing, as well as customary events of default.

10-Q filed Jul 30, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Apr 30, 2026: 5 added · 5 removed · 93 modified; 2 with only figures updated

103 more changes in this Item, word by word, in Powerpack.